Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. The aim was a "common rubric" for long-term studies to test which factors best predict who moves from normal cognition to mild cognitive impairment and dementia; it is an expert proposal, not a study that tested patients. The authors state the criteria are "solely intended for research purposes and do not have any clinical implications at this time," and that the link between the disease process and symptoms still needs to be clarified.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2011.03.003

Vancouver

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011. doi:10.1016/j.jalz.2011.03.003. PMID: 21514248.

BibTeX

@article{sperling2011-21514248,
  author  = {Sperling, R. A. and Aisen, P. S. and Beckett, L. A. and Bennett, D. A. and Craft, S. and Fagan, A. M. and Iwatsubo, T. and Jack, C. R. and others},
  title   = {{Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2011},
  doi     = {10.1016/j.jalz.2011.03.003},
  pmid    = {21514248},
  url     = {https://doi.org/10.1016/j.jalz.2011.03.003}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 2011 an international expert workgroup convened by the National Institute on Aging and the Alzheimer's Association proposed research criteria for a "preclinical" stage of Alzheimer's disease, the years when the disease process "is thought to begin" before dementia is diagnosed. The aim was a "common rubric" for long-term studies to test which factors best predict who moves from normal cognition to mild cognitive impairment and dementia; it is an expert proposal, not a study that tested patients. The authors state the criteria are "solely intended for research purposes and do not have any clinical implications at this time," and that the link between the disease process and symptoms still needs to be clarified.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 6 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 7,154 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 420.8 citations a year over 17 year(s) since 2011
Impact for its field and year 6 / 6 Cited 251.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 6 / 6 Cited by 469 other studies in this library
Still being cited 4 / 4 Cited 1,305 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Creighton H. Phelps: h-index 26 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 23 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21514248)
Free to read 0 / 2 Behind a paywall — scores zero
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.

Later studies that cite this one

469 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also in Getting a diagnosis

141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →